Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting.
Lobby members of Congress regarding issues related to telemedicine.
Advocate for increased transparency regarding drug pricing.
Lobby members of the House to join the Congressional Skin Cancer Caucus.
Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Support H.R. 1959, Preserving Patient Access to Compounded Medications Act.
Support H.R. 2077/S. 2546, Safe Step Act.
Support H.R. 1035, Prescription Drug Price Transparency Act.
Support H.R. 985, Fair Access for Safe and Timely Generics Act.
Support reintroduction of Patients Access to Treatments Act.
Support S. 476, C-THRU Act.
Support S. 989, Ensuring Childrens Access to Specialty Care Act.
Support H.R. 1034/S. 640, Phair Pricing Act.
Support S. 657, Drug Price Transparency Act
Support H.R. 938, BLOCKING Act
Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act
Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act
Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act
Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act.
Support H.R. 2115, Public Disclosure of Drug Discounts Act
Support H.R. 2376/S. 1227, Prescription Pricing for the People Act
Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act.
Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Support H.R. 3107, Seniors Timely Access to Care Act
Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act.
Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs.
Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act
Support H.R. 1554, Resident Education Deferred Interest (REDI) Act.
Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182).
Advocate for the continued and increased funding of Community Health Centers.
Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers.
Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Support legislation to address drug shortages by providing additional authority to the Food and Drug Administration (FDA) to ensure a stable supply of medications (S. 2723, Mitigating Emergency Drug Shortages Act; H.R. 6080, Preventing Drug Shortages Act). Similar provisions to mitigate drug shortages included in CARES Act (H.R. 748, S. 3548).
Request resources to provide personal protection equipment (PPE) and supplies and relief from Medicare payment sequester and relief from penalties in Merit-based Incentive Payment System (MIPS) under MACRA in the CARES Act (H.R. 748, S. 3548).

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2021 Labor, Health and Human Services, Education and Related Agencies Appropriations bill.
Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 21 Department of Defense Appropriations bill.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage.
Advocate for increased funding and reforms to Graduate Medical Education.
Lobby members of Congress regarding improvements to Health Information Technology implementation.
Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services.
Advocate for improving disease management and care coordination for patients with chronic diseases.
Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception.
Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019.
Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110)
Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019
Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS).
Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Support H.R. 3107, Seniors Timely Access to Care Act
Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program.
Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs).
Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs.
Support H.R. 3302, Keep Physicians Serving Patients Act.
Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services
Request relief from Medicare payment sequester and relief from penalties in Merit-based Incentive Payment System (MIPS) under MACRA in the CARES Act (H.R. 748, S. 3548).

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs. (S.1089/H.R.1922, Restoring Access to Medication Act, H.R. 748, S. 3548)
Oppose legislation to repeal the excise tax on indoor tanning services (H.R. 5512, S. 2713)
Advocate for economic relief for physicians who have been adversely affected by the COVID-19 epidemic. (H.R. 748, S. 3548)
Advocate for the inclusion of 501(c)6 non-profit associations to be included in the Payroll Protection Program as part of the CARES Act (H.R. 748, S. 3548).

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting.
Support H.R. 1959, Preserving Patient Access to Compounded Medications Act
Support H.R. 1035, Prescription Drug Price Transparency Act
Support S. 476, C-THRU Act.
Support H.R. 1034/S. 640, Phair Pricing Act.
Support S. 657, Drug Price Transparency Act.
H.R. 2115, Public Disclosure of Drug Discounts Act
H.R. 2376/S. 1227, Prescription Pricing for the People Act
Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (Provisions included in CARES Act, H.R. 748).
Support legislation to address drug shortages by providing additional authority to the Food and Drug Administration (FDA) to ensure a stable supply of medications (S. 2723, Mitigating Emergency Drug Shortages Act; H.R. 6080, Preventing Drug Shortages Act). Similar provisions to mitigate drug shortages included in CARES Act (H.R. 748, S. 3548).

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2021 Labor, Health and Human Services, Education and Related Agencies Appropriations bill.
Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY2021 Department of Defense Appropriations bill.
Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 748).
Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 1865/P.L. 116-94).

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 1865/P.L. 116-94)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes